Our preclinical findings in bladder cancer models highlight that TAK‐228 functions not only as an anti‐tumor agent but also triggers changes within tumor cells, such as de novo protein synthesis and adjustments in cell surface molecules like PD‐L1. Here, CD274 is linked to urinary bladder cancer.